Cargando…

The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines

SIMPLE SUMMARY: Rhabdomyosarcoma is the most common soft tissue tumor in children. Its two major subtypes show epigenetic alterations that are associated with poor prognosis. Therefore, targeting these epigenetic alterations by pharmacological intervention could be a therapeutic approach. We investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Andreas, Behrendt, Lucas, Eybe, Jana, Warmann, Steven W., Schleicher, Sabine, Fuchs, Joerg, Schmid, Evi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750739/
https://www.ncbi.nlm.nih.gov/pubmed/35008205
http://dx.doi.org/10.3390/cancers14010041
_version_ 1784631529591275520
author Schmidt, Andreas
Behrendt, Lucas
Eybe, Jana
Warmann, Steven W.
Schleicher, Sabine
Fuchs, Joerg
Schmid, Evi
author_facet Schmidt, Andreas
Behrendt, Lucas
Eybe, Jana
Warmann, Steven W.
Schleicher, Sabine
Fuchs, Joerg
Schmid, Evi
author_sort Schmidt, Andreas
collection PubMed
description SIMPLE SUMMARY: Rhabdomyosarcoma is the most common soft tissue tumor in children. Its two major subtypes show epigenetic alterations that are associated with poor prognosis. Therefore, targeting these epigenetic alterations by pharmacological intervention could be a therapeutic approach. We investigated two different types of substances that interfere with the epigenetic process of histone methylation. We performed studies in two cell lines that carry characteristics of the major rhabdomyosarcoma subtypes. The aim of this study was to find out if the substances differ in their effect on tumor-related cellular functions and to find out if the tumor subtypes differ in their response to the substances. These findings may contribute to a better assessment of the feasibility of pharmacological intervention directed against histone methylation in subtypes of rhabdomyosarcoma. ABSTRACT: Enhancer of Zeste homolog 2 (EZH2) is involved in epigenetic regulation of gene transcription by catalyzing trimethylation of histone 3 at lysine 27. In rhabdomyosarcoma (RMS), increased EZH2 protein levels are associated with poor prognosis and increased metastatic potential, suggesting EZH2 as a therapeutic target. The inhibition of EZH2 can be achieved by direct inhibition which targets only the enzyme activity or by indirect inhibition which also affects activities of other methyltransferases and reduces EZH2 protein abundance. We assessed the direct inhibition of EZH2 by EPZ005687 and the indirect inhibition by 3-deazaneplanocin (DZNep) and adenosine dialdehyde (AdOx) in the embryonal RD and the alveolar RH30 RMS cell line. EPZ005687 was more effective in reducing the cell viability and colony formation, in promoting apoptosis induction, and in arresting cells in the G1 phase of the cell cycle than the indirect inhibitors. DZNep was more effective in decreasing spheroid viability and size in both cell lines than EPZ005687 and AdOx. Both types of inhibitors reduced cell migration of RH30 cells but not of RD cells. The results show that direct and indirect inhibition of EZH2 affect cellular functions differently. The alveolar cell line RH30 is more sensitive to epigenetic intervention than the embryonal cell line RD.
format Online
Article
Text
id pubmed-8750739
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87507392022-01-12 The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines Schmidt, Andreas Behrendt, Lucas Eybe, Jana Warmann, Steven W. Schleicher, Sabine Fuchs, Joerg Schmid, Evi Cancers (Basel) Article SIMPLE SUMMARY: Rhabdomyosarcoma is the most common soft tissue tumor in children. Its two major subtypes show epigenetic alterations that are associated with poor prognosis. Therefore, targeting these epigenetic alterations by pharmacological intervention could be a therapeutic approach. We investigated two different types of substances that interfere with the epigenetic process of histone methylation. We performed studies in two cell lines that carry characteristics of the major rhabdomyosarcoma subtypes. The aim of this study was to find out if the substances differ in their effect on tumor-related cellular functions and to find out if the tumor subtypes differ in their response to the substances. These findings may contribute to a better assessment of the feasibility of pharmacological intervention directed against histone methylation in subtypes of rhabdomyosarcoma. ABSTRACT: Enhancer of Zeste homolog 2 (EZH2) is involved in epigenetic regulation of gene transcription by catalyzing trimethylation of histone 3 at lysine 27. In rhabdomyosarcoma (RMS), increased EZH2 protein levels are associated with poor prognosis and increased metastatic potential, suggesting EZH2 as a therapeutic target. The inhibition of EZH2 can be achieved by direct inhibition which targets only the enzyme activity or by indirect inhibition which also affects activities of other methyltransferases and reduces EZH2 protein abundance. We assessed the direct inhibition of EZH2 by EPZ005687 and the indirect inhibition by 3-deazaneplanocin (DZNep) and adenosine dialdehyde (AdOx) in the embryonal RD and the alveolar RH30 RMS cell line. EPZ005687 was more effective in reducing the cell viability and colony formation, in promoting apoptosis induction, and in arresting cells in the G1 phase of the cell cycle than the indirect inhibitors. DZNep was more effective in decreasing spheroid viability and size in both cell lines than EPZ005687 and AdOx. Both types of inhibitors reduced cell migration of RH30 cells but not of RD cells. The results show that direct and indirect inhibition of EZH2 affect cellular functions differently. The alveolar cell line RH30 is more sensitive to epigenetic intervention than the embryonal cell line RD. MDPI 2021-12-23 /pmc/articles/PMC8750739/ /pubmed/35008205 http://dx.doi.org/10.3390/cancers14010041 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schmidt, Andreas
Behrendt, Lucas
Eybe, Jana
Warmann, Steven W.
Schleicher, Sabine
Fuchs, Joerg
Schmid, Evi
The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
title The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
title_full The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
title_fullStr The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
title_full_unstemmed The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
title_short The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
title_sort effect of direct and indirect ezh2 inhibition in rhabdomyosarcoma cell lines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750739/
https://www.ncbi.nlm.nih.gov/pubmed/35008205
http://dx.doi.org/10.3390/cancers14010041
work_keys_str_mv AT schmidtandreas theeffectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT behrendtlucas theeffectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT eybejana theeffectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT warmannstevenw theeffectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT schleichersabine theeffectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT fuchsjoerg theeffectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT schmidevi theeffectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT schmidtandreas effectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT behrendtlucas effectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT eybejana effectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT warmannstevenw effectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT schleichersabine effectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT fuchsjoerg effectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines
AT schmidevi effectofdirectandindirectezh2inhibitioninrhabdomyosarcomacelllines